Phase 1/2

Promising Results in a Phase I/II Clinical Trial

The Phase 1/2 clinical trial was conducted on twelve terminal recurrent Glioblastoma Multiforme (GBM) patients at the Hadassah Ein Kerem Medical Center using the NADAV virus.

Phase I/II Clinical Trial for Recurrent Glioblastoma Multiforme

PROMISING
RESULTS

12 terminal GBM patients at Hadassah Ein-Kerem Medical Center

IV treatment

01

4 patients responded:
observable tumor shrinkage,
 extended  survival rate

02

1 responsive patient showed complete response

03

No patients showed significant side effects

PROMISING
RESULTS

12 terminal GBM patients at Hadassah Ein-Kerem Medical Center

IV treatment

4 patients responded:
observable tumor shrinkage,
 extended  survival rate

1 responsive patient showed complete response

No patients showed significant side effects

(A)  Patient  at baseline

(B) Stable disease at first follow-up

(C) Partial response (PR) at second follow-up

(D) PR at 20 weeks from start of viro-therapy

(E and F) Complete response at 25 and30 weeks from start of viro-therapy

NADAV Study Advantages

The response rate achieved by NADAV in the clinical trial, is among the best results published to date with other oncolytic virus therapy or treatments being applied to recurrent GBM.

None of the patients developed any severe side effects demonstrating the high safety profile of the NADAV administration.

The high safety level of administration of NADAV IV, can lead to the treatment of related metastases from the primary tumor.